Magnolia Medical Launches New Corporate Website to Educate Healthcare Providers About Blood Culture Contamination and Increase Awareness of the Devastating Impact of Misdiagnosing Sepsis
The website also supports Magnolia Medical’s mission to zero® country. For every person who signs the pledge to prevent misdiagnosis of sepsis for better patient outcomes, Magnolia Medical will donate to the Sepsis Alliance.
SEATTLE, June 2, 2022 /PRNewswire/ — Magnolia Medical Technologies, Inc., inventors of Steripath®the only FDA 510(k) cleared device platform specifically indicated to reduce blood culture contamination for sepsis testing accuracy,1 today announced the launch of its new website (www.magnolia-medical.com).
Magnolia-Medical.com supports the company’s mission to dramatically improve the diagnostic accuracy of sepsis testing to directly, immediately, and meaningfully enable antibiotic stewardship initiatives, prevent patient harm, and improve patient outcomes.
One of the primary goals of the website is to educate the healthcare community about the role of diagnostic management in antimicrobial stewardship and quality outcomes, and how technological solutions, such as the Steripath® Initial sample diversion device®align with these goals by designing for compliance and ensuring equity of care in hospitals and health systems.
The website provides a simplified user interface for improved navigation and has been designed to accommodate Magnolia Medical’s extensive educational offerings. Magnolia-Medical.com also offers on-demand content specifically curated for nursing, infection control, quality, laboratory and hospital administration stakeholders on specific pain points these departments may encounter. due to blood culture contamination and the clinical and economic implications of misdiagnosis of sepsis.
In addition, the website allows health care providers and institutions to sign the mission to zero® commit and unite around a common cause of eliminating misdiagnosis of sepsis due to the avoidable error of false positive blood culture results. For each person who signs the pledge, “I am committed to helping prevent misdiagnoses of sepsis by providing diagnostic excellence and the highest level of patient care possible,” Magnolia Medical will make a donation to Sepsis Alliance to support its efforts to raise awareness of the devastating impact of sepsis on patients and the community while advocating for improvements in sepsis care.
“Magnolia-Medical.com was developed as a comprehensive resource to educate the healthcare community about evidence-based approaches to dramatically improve patient safety and quality outcomes through sepsis testing accuracy,” said Greg Bullington, CEO of Magnolia Medical. “Recognizing the immense time and resource constraints healthcare professionals face in today’s environment, the new site has been designed to provide an easy-to-navigate ‘one-stop’ resource where essential information about the problem, cause and the solution of a misdiagnosis of sepsis are readily available. .”
“I am also delighted to support Sepsis Alliance in raising awareness of sepsis and the urgent need to seek treatment when symptoms are recognized,” continued Bullington. “Magnolia Medical’s mission is to improve the accuracy of sepsis testing. With Steripath, we can increase clinicians’ confidence in blood culture results, enabling safer and more effective treatment decisions for patients with suspected sepsis.
Magnolia Medical invites visitors to explore its new website at http://www.magnolia-medical.com/ and reminds them to sign the pledge to our collective mission to zero® and in support of Sepsis Alliance.
About Magnolia Medical Technologies
Magnolia Medical Technologies develops, manufactures and markets innovative blood and body fluid collection devices to facilitate significant improvements in the accuracy, consistency and predictability of critical laboratory testing. Magnolia Medical invented and patented the original sample derivation technique® (ISDT®) and initial sample deviation device® (ISDD®) for the collection of blood cultures and the prevention of contamination. The company has built an intellectual property portfolio, including over 100 issued method, device and design patents and over 70 additional patent applications pending. For more information, visit http://www.magnolia-medical.com/.
1. Indicated to reduce the frequency of contamination of blood cultures when contaminants are present, compared to non-diversion standard method controls.
SOURCEMagnolia Medical Technologies